PharmaResearch Co., Ltd.
KOSDAQ
₩342,000.00
-2.15%
Delayed · cached 15 min
Fair value analysis
214450
PharmaResearch Co., Ltd.
₩342,000.00
Close used for this calculation
₩343,962.75Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
67/100
Quality radar
Consensus fair value
₩343,962.75
Near FV▲ +0.6% against the close used
Model range ₩149,373.73 – ₩965,667.33
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩149,373.73Fair value₩343,962.75Bull₩965,667.33
FairClose
52-week traded range
52W low ₩322,500.0052W high ₩461,500.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
PharmaResearch Co., Ltd. closed at ₩342,000.00, 0.6% below the consensus fair value of ₩343,962.75 drawn from 9 valuation models.
Financial DNA score 67/100 — Strong. P/E of 22.9x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩270,297.35
-21.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₩149,373.73
-56.3%
√(22.5 × EPS × BVPS)
EPS=14933, BVPS=66407.77 · outside Graham range (P/E 22.9, P/B 5.2) — asset-light, treat as a rough floor
Graham Formula
₩965,667.33
+182.4%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=20%, FD=3.3%
P/E Fair Value
₩298,660.00
-12.7%
EPS × 20x (sector P/E)
EPS=14933, Sector P/E=20x
Peter Lynch (PEG)
₩447,990.00
+31.0%
EPS × Growth% (PEG = 1 is fair)
EPS=14933, g=30%
EV/EBITDA
₩342,462.48
+0.1%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=214.4B
Book Value (P/B)
₩298,004.85
-12.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=66407.77, ROE=24%, g=6%, r=10%
Reverse DCF
₩342,000.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 9% | Historical: 49.9%
Margin of Safety
₩315,749.70
-7.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=420999.6, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.